Background: Stable angina reflects chronic coronary atherosclerotic disease in which ischemic symptoms interact with hemodynamic, lipid, inflammatory, oxidative, and occupational risk factors. Objective: To characterize the pretreatment clinical, functional, and metabolic profile of patients with stable angina assigned to different therapeutic groups before evaluating HMG-CoA reductase inhibitor-based regimens. Methods: The baseline analysis included 150 participants: 30 controls and 120 patients with stable angina distributed equally across four clinical groups. Occupational categories included medical professionals, programmers, marketing specialists, and drivers. Assessment comprised angina frequency, nitroglycerin use, Holter electrocardiography, ambulatory blood pressure monitoring, bicycle ergometry, lipid profile, apolipoprotein B, C-reactive protein, malondialdehyde, superoxide dismutase, catalase, ceruloplasmin, and nitric oxide metabolites. Results: Compared with controls, patients had higher LDL-C, apoB, CRP, MDA, blood pressure, heart rate, arrhythmic burden, and daily ST-segment depression, together with lower HDL-C, antioxidant enzyme activity, NOx, exercise threshold, and exercise duration. LDL-C correlated positively with MDA (r = .41) and ST-depression depth (r = .34) and inversely with NOx (r = -.47). Occupational risk patterns differed, particularly for smoking, night shifts, and stress. Conclusion: Stable angina was associated with a coordinated atherogenic, inflammatory, oxidative, endothelial, and functional phenotype before treatment. These findings provide a balanced baseline for subsequent evaluation of atorvastatin-containing regimens but do not independently establish therapeutic efficacy.
1. Bogaty, P., Dagenais, G. R., Poirier, P., Boyer, L., Auclair, L., Pépin, G., Jobin, J., & Arsenault, M. (2003). Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris. American Journal of Cardiology, 92(10), 1192-1195. https://doi.org/10.1016/j.amjcard.2003.08.001
2. Cholesterol Treatment Trialists’ (CTT) Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
3. Cholesterol Treatment Trialists’ (CTT) Collaborators. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590. https://doi.org/10.1016/S0140-6736(12)60367-5
4. Deanfield, J. E., Sellier, P., Thaulow, E., Bultas, J., Yunis, C., Shi, H., Buch, J., & Beckerman, B. (2010). Potent anti-ischaemic effects of statins in chronic stable angina: Incremental benefit beyond lipid lowering? European Heart Journal, 31(21), 2650-2659. https://doi.org/10.1093/eurheartj/ehq133
5. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M.-R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
6. Fu, Y., Wu, Y., & Liu, E. (2020). C-reactive protein and cardiovascular disease: From animal studies to the clinic. Experimental and Therapeutic Medicine, 20(2), 1211-1219. https://doi.org/10.3892/etm.2020.8840
7. Qu, H., Guo, M., Chai, H., Wang, W.-T., Gao, Z.-Y., & Shi, D.-Z. (2018). Effects of coenzyme Q10 on statin-induced myopathy: An updated meta-analysis of randomized controlled trials. Journal of the American Heart Association, 7(19), e009835. https://doi.org/10.1161/JAHA.118.009835
8. Ridker, P. M. (2004). High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit. American Heart Journal, 148(1 Suppl.), S19-S26. https://doi.org/10.1016/j.ahj.2004.04.028
9. Simantiris, S., Papastamos, C., Antonopoulos, A. S., Theofilis, P., Sagris, M., Bounta, M., Konisti, G., Galiatsatos, N., Xanthaki, A., Tsioufis, K., & Tousoulis, D. (2023). Oxidative stress biomarkers in coronary artery disease. Current Topics in Medicinal Chemistry, 23(22), 2158-2171. https://doi.org/10.2174/1568026623666230502140614
10. Soffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., Dixon, D. L., Ballantyne, C. M., & Remaley, A. T. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the National Lipid Association. Journal of Clinical Lipidology, 18(5), e647-e663. https://doi.org/10.1016/j.jacl.2024.08.013
11. Stone, P. H., Lloyd-Jones, D. M., Kinlay, S., Frei, B., Carlson, W., Rubenstein, J., Andrews, T. C., Johnstone, M., Sopko, G., Cole, H., Orav, J., Selwyn, A. P., & Creager, M. A., for the Vascular Basis Study Group. (2005). Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: The Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation, 111(14), 1747-1755. https://doi.org/10.1161/01.CIR.0000160866.90148.76
12. Torquati, L., Mielke, G. I., Brown, W. J., & Kolbe-Alexander, T. (2018). Shift work and the risk of cardiovascular disease: A systematic review and meta-analysis including dose-response relationship. Scandinavian Journal of Work, Environment & Health, 44(3), 229-238. https://doi.org/10.5271/sjweh.3700
13. Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., ... Williams, M. S. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 148(9), e9-e119. https://doi.org/10.1161/CIR.0000000000001168
14. Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., Chieffo, A., Christodorescu, R. M., Deaton, C., Doenst, T., Jones, H. W., Kunadian, V., Mehilli, J., Milojevic, M., Piek, J. J., ... Winther, S. (2024). 2024 ESC guidelines for the management of chronic coronary syndromes. European Heart Journal, 45(36), 3415-3537. https://doi.org/10.1093/eurheartj/ehae177
15. Xu, S., Huang, Y., Xiao, J., Zhu, W., Wang, L., Tang, H., Hu, Y., & Liu, T. (2015). The association between job strain and coronary heart disease: A meta-analysis of prospective cohort studies. Annals of Medicine, 47(6), 512-518. https://doi.org/10.3109/07853890.2015.1075658
How to Cite
Turaev Shoyimardon, Azizova Farida (2026). THE ROLE OF HMG-COA REDUCTASE INHIBITORS IN STABLE ANGINA ACROSS OCCUPATIONAL GROUPS: BASELINE CLINICAL, FUNCTIONAL, AND METABOLIC CHARACTERIZATION. Science and Innovation, 5(8), 63-70. https://doi.org/10.67620/sai.58d0008